Advertisement
Screener

MACROGENICS, INC. (MGNX) Graph

MGNX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $32.83M; Cost of revenue (m); Research and development $38.78M; Income tax $0.00.
  • 2026-03-31: Revenue $20.77M; Cost of revenue (m); Research and development $34.97M; Income tax (m).
  • 2025-12-31: Revenue $41.23M*; Cost of revenue $0.00*; Research and development $33.97M*; Income tax -$777.00K*.
  • 2025-09-30: Revenue $72.84M; Cost of revenue $0.00; Research and development $32.71M; Income tax $0.00.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

MGNX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue FromCollaborative Agreements$25.49MRevenue From RoyalityAgreements Member$7.34MRevenue$32.83MOperating income-$13.85MResearch & development$38.78MPre-tax income-$69.64MIncome tax$0.00Net income$19.52M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

MGNX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Main Segment$32.83MRevenue$32.83MOperating income-$13.85MResearch & development$38.78MPre-tax income-$69.64MIncome tax$0.00Net income$19.52M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2026-06-30$32.83M(m)$38.78M$0.00$19.52M
2026-03-31$20.77M(m)$34.97M(m)-$36.77M
2025-12-31$41.23M*$0.00*$33.97M*-$777.00K*$60.39M*
2025-09-30$72.84M$0.00$32.71M$0.00$16.82M
2025-06-30$6.87M$0.00$40.79M$105.00K-$36.25M
2025-03-31$13.19M$0.00$39.70M(m)-$41.04M
2024-09-30$110.71M$168.00K$40.54M$0.00$56.31M
2024-06-30$10.80M$176.00K$51.73M$0.00-$55.66M
2024-03-31$9.10M$270.00K$46.03M(m)-$52.19M
2023-09-30$10.40M$85.00K$30.13M(m)$17.55M
2023-06-30$13.14M$258.00K$43.23M(m)$57.47M
2023-03-31$24.50M$113.00K$45.87M(m)-$38.01M
2022-09-30$41.73M$3.01M$48.19M(m)-$24.81M
2022-06-30$26.01M$180.00K$51.74M(m)-$41.30M
2022-03-31$11.10M$48.00K$61.44M(m)-$66.44M
2021-09-30$15.66M$1.67M$49.82M(m)-$52.89M
2021-06-30$30.76M$22.00K$55.78M(m)-$39.94M
2021-03-31$16.88M$17.00K$53.12M(m)-$51.27M
2020-09-30$18.25M$0.00$44.66M(m)-$36.04M
2020-06-30$20.26M$0.00$57.35M(m)-$46.88M
2020-03-31$13.68M$0.00$48.89M(m)-$44.72M
2019-12-31$25.19M(m)(m)(m)-$30.40M
2019-09-30$18.74M(m)$44.85M(m)-$44.63M
2019-06-30$10.59M(m)$51.44M(m)-$31.77M
2019-03-31$9.66M(m)$47.06M(m)-$45.02M
2018-12-31$15.79M(m)(m)(m)-$44.64M
2018-09-30$20.80M(m)$46.22M(m)-$34.03M
2018-06-30$18.83M(m)$52.01M(m)-$43.24M
2018-03-31$4.70M(m)$45.67M(m)-$49.54M
2017-12-31$152.36M(m)(m)(m)$105.73M
2017-09-30$1.66M(m)$40.98M(m)-$47.04M
2017-06-30$1.67M(m)$34.46M(m)-$40.65M
2017-03-31$2.06M(m)$32.80M(m)-$37.66M
2016-12-31$5.11M(m)(m)(m)-$34.78M
2016-09-30$3.25M(m)$30.30M(m)-$33.85M
2016-06-30$80.67M(m)$33.34M(m)$40.46M
2016-03-31$2.85M(m)$27.35M(m)-$30.36M
2015-12-31$8.18M(m)(m)(m)-$28.45M
2015-09-30$14.68M(m)$24.10M(m)-$15.44M
2015-06-30$6.72M(m)$22.66M(m)-$21.38M
2015-03-31$71.28M(m)$21.46M(m)$45.13M
2014-12-31$5.48M(m)(m)(m)-$19.02M
2014-09-30$18.38M(m)$18.63M(m)-$3.93M
2014-06-30$9.22M(m)$17.34M(m)-$12.26M
2014-03-31$14.72M(m)$14.57M(m)-$3.11M
2013-12-31$14.91M(m)(m)(m)-$3.21M
2013-09-30$20.23M(m)$11.09M(m)$6.60M
2013-06-30$12.30M(m)$11.05M(m)-$294.00K
2013-03-31$10.60M(m)$10.10M(m)-$3.37M
2012-12-31$9.80M(m)(m)(m)-$2.10M
2012-09-30$16.08M(m)$11.97M(m)$2.60M
2012-06-30$17.43M(m)(m)(m)$3.55M
2012-03-31$20.51M(m)(m)(m)$4.32M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2026-06-30$39.55M(m)$73.75M$0.00-$17.26M
2025-06-30$13.91M$0.00$80.49M$105.00K-$77.29M
2024-06-30$19.90M$446.00K$97.76M$0.00-$107.85M
2023-06-30$37.63M$371.00K$89.10M(m)$19.46M
2022-06-30$37.11M$228.00K$113.18M(m)-$107.75M
2021-06-30$47.64M$39.00K$108.90M(m)-$91.21M
2020-06-30$33.94M$0.00$106.25M(m)-$91.61M
2019-06-30$20.25M(m)$98.50M(m)-$76.78M
2018-06-30$23.53M(m)$97.68M(m)-$92.78M
2017-06-30$3.72M(m)$67.26M(m)-$78.31M
2016-06-30$83.52M(m)$60.69M(m)$10.10M
2015-06-30$78.00M(m)$44.12M(m)$23.75M
2014-06-30$23.94M(m)$31.90M(m)-$15.37M
2013-06-30$22.90M(m)$21.15M(m)-$3.66M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-09-30$108.27M$0.00$113.20M$105.00K-$60.47M
2024-09-30$130.61M$614.00K$138.30M$0.00-$51.55M
2023-09-30$48.03M$456.00K$119.23M(m)$37.01M
2022-09-30$78.84M$3.23M$161.37M(m)-$132.56M
2021-09-30$63.30M$1.70M$158.72M(m)-$144.09M
2020-09-30$52.19M$0.00$150.90M(m)-$127.65M
2019-09-30$39.00M(m)$143.35M(m)-$121.42M
2018-09-30$44.33M(m)$143.90M(m)-$126.81M
2017-09-30$5.38M(m)$108.25M(m)-$125.35M
2016-09-30$86.77M(m)$90.98M(m)-$23.75M
2015-09-30$92.68M(m)$68.23M(m)$8.31M
2014-09-30$42.32M(m)$50.54M(m)-$19.30M
2013-09-30$43.13M(m)$32.23M(m)$2.94M
2012-09-30$54.03M(m)$36.92M(m)$10.47M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-12-31$149.50M$0.00$147.17M-$672.00K-$74.62K
2024-12-31$149.96M$847.00K$177.19M$944.00K-$66.97K
2023-12-31$58.75M$619.00K$166.58M$0.00-$9.06K
2022-12-31$151.94M$3.35M$207.03M$0.00-$119.76M
2021-12-31$77.45M$2.65M$214.58M$0.00-$202.12M
2020-12-31$104.88M$0.00$193.20M$0.00-$129.74M
2019-12-31$64.19M$0.00$195.31M$0.00-$151.81M
2018-12-31$60.12M(m)$190.83M$0.00-$171.45M
2017-12-31$157.74M(m)$147.23M$0.00-$19.63M
2016-12-31$91.88M(m)$122.09M$0.00-$58.53M
2015-12-31$100.85M(m)$98.27M$0.00-$20.14M
2014-12-31$47.80M(m)$70.19M$0.00-$38.31M
2013-12-31$58.03M(m)$46.58M$0.00-$261.00K
2012-12-31$63.83M(m)$45.43M$0.00$8.36M
2011-12-31$57.21M(m)$41.09M(m)$6.72M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35